CN113226326B - 有机化合物 - Google Patents

有机化合物 Download PDF

Info

Publication number
CN113226326B
CN113226326B CN201980083634.9A CN201980083634A CN113226326B CN 113226326 B CN113226326 B CN 113226326B CN 201980083634 A CN201980083634 A CN 201980083634A CN 113226326 B CN113226326 B CN 113226326B
Authority
CN
China
Prior art keywords
disorders
compound
compound according
disorder
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980083634.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113226326A (zh
Inventor
K·瓦诺维尔
李鹏
R·戴维斯
乔玉普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CN113226326A publication Critical patent/CN113226326A/zh
Application granted granted Critical
Publication of CN113226326B publication Critical patent/CN113226326B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN201980083634.9A 2018-12-17 2019-12-17 有机化合物 Active CN113226326B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780703P 2018-12-17 2018-12-17
US62/780,703 2018-12-17
PCT/US2019/066923 WO2020131918A1 (en) 2018-12-17 2019-12-17 Organic compounds

Publications (2)

Publication Number Publication Date
CN113226326A CN113226326A (zh) 2021-08-06
CN113226326B true CN113226326B (zh) 2024-09-20

Family

ID=71100855

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980083634.9A Active CN113226326B (zh) 2018-12-17 2019-12-17 有机化合物

Country Status (11)

Country Link
US (1) US12325726B2 (https=)
EP (1) EP3897656A4 (https=)
JP (1) JP7645797B2 (https=)
KR (1) KR102931436B1 (https=)
CN (1) CN113226326B (https=)
AU (1) AU2019406803B2 (https=)
BR (1) BR112021011765A2 (https=)
CA (1) CA3121636A1 (https=)
IL (1) IL283960B2 (https=)
MX (1) MX2021007142A (https=)
WO (1) WO2020131918A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
AU2019406803B2 (en) 2018-12-17 2025-04-24 Intra-Cellular Therapies, Inc. Organic compounds
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
JP2023539125A (ja) * 2020-08-20 2023-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2023159094A2 (en) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1360591A (zh) * 1999-04-29 2002-07-24 皮杜制药有限公司 具有麻醉剂活性的3α－羟基－3β－甲氧基甲基－21－杂环取代的类固醇
CN101193640A (zh) * 2005-06-09 2008-06-04 欧洲凯尔特公司 神经活性甾族化合物的药物组合物及其用途
WO2016134301A2 (en) * 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN107404877A (zh) * 2014-10-16 2017-11-28 萨奇治疗股份有限公司 靶向cns 障碍的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
KR100338287B1 (ko) 1994-02-14 2002-11-30 푸르듀 파머 리미티드 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
ME03809B (me) * 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
AU2019406803B2 (en) 2018-12-17 2025-04-24 Intra-Cellular Therapies, Inc. Organic compounds
JP2023539125A (ja) 2020-08-20 2023-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1360591A (zh) * 1999-04-29 2002-07-24 皮杜制药有限公司 具有麻醉剂活性的3α－羟基－3β－甲氧基甲基－21－杂环取代的类固醇
CN101193640A (zh) * 2005-06-09 2008-06-04 欧洲凯尔特公司 神经活性甾族化合物的药物组合物及其用途
CN107404877A (zh) * 2014-10-16 2017-11-28 萨奇治疗股份有限公司 靶向cns 障碍的组合物和方法
WO2016134301A2 (en) * 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Also Published As

Publication number Publication date
MX2021007142A (es) 2021-08-11
JP7645797B2 (ja) 2025-03-14
JP2022513933A (ja) 2022-02-09
AU2019406803A1 (en) 2021-07-08
KR102931436B1 (ko) 2026-02-25
IL283960B2 (en) 2025-09-01
BR112021011765A2 (pt) 2021-08-31
CN113226326A (zh) 2021-08-06
CA3121636A1 (en) 2020-06-25
US20220073558A1 (en) 2022-03-10
WO2020131918A1 (en) 2020-06-25
IL283960A (en) 2021-07-29
EP3897656A1 (en) 2021-10-27
AU2019406803B2 (en) 2025-04-24
EP3897656A4 (en) 2022-09-21
KR20210105934A (ko) 2021-08-27
US12325726B2 (en) 2025-06-10
IL283960B1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
CN113226326B (zh) 有机化合物
JP2023539125A (ja) 有機化合物
EP3438107B1 (en) Substituted quinazoline compound having blood-brain barrier penetration capability
AU2017238858A1 (en) Methods of using (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
RS62133B1 (sr) Tetrahidro-1h-pirido[3,4-b]indol antiestrogeni lekovi
CN114206899A (zh) 3-羟基-5-孕烷-20-酮衍生物及其用途
CA3182354A1 (en) Methyl 2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1h-cyclopenta[b]pyridine-3-carboxylates and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylates as cav1.2 activators
CN103635446B (zh) 戊四唑衍生物
JP2021519276A (ja) Ｄ−β−ヒドロキシ酪酸の重水素化類似体およびその使用
CN111201016A (zh) 针对情绪疾患的新型γ氨基丁酸A型受体调节剂
JP7750582B2 (ja) 水溶性アロプレグナノロン誘導体及びその製造方法並びに用途
US20240025874A1 (en) Quinazoline Derivative Salt Crystal Form, Preparation Method and Application
RU2809023C2 (ru) Органические соединения
HK40058207A (en) Organic compounds
EP4165048B1 (en) Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4- b]pyridine-3-carboxylate compounds as cav1.2 activators
HK40058207B (zh) 有机化合物
EP3778589B1 (en) 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
JP2024545200A (ja) ＣａＶ１．２活性剤としてのピリジン－３－カルボキシレート化合物
WO2024091943A2 (en) Deuterated analogs of etifoxine and methods of administration without autoinduction of metabolism

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058207

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant